IPO & SPAC Market Update: Q3 2026 FTI Consulting
Corxel claims oral obesity drug is in the ‘right lane’ as biotech plans SPAC route to Nasdaq – Fierce Biotech
Corxel claims oral obesity drug is in the ‘right lane’ as biotech plans SPAC route to Nasdaq Fierce Biotech
Corxel, an obesity drugmaker, to go public via SPAC deal – BioPharma Dive
Corxel, an obesity drugmaker, to go public via SPAC deal BioPharma Dive
Obesity drug developer Corxel to go public in US via SPAC deal – Reuters
Obesity drug developer Corxel to go public in US via SPAC deal Reuters
Corxel to take oral GLP-1 public in the US via SPAC – Endpoints News
Corxel to take oral GLP-1 public in the US via SPAC Endpoints News
Broker admits role in SPAC insider trading – Investment Executive
Broker admits role in SPAC insider trading Investment Executive
Obesity drug developer Corxel to go public in US via SPAC deal – KELO-AM
Obesity drug developer Corxel to go public in US via SPAC deal KELO-AM
Nice Work If You Can Getty – Puck
Nice Work If You Can Getty Puck
Elroy Air CEO details Chaparral drone ahead of $961M SPAC merger – Dealroom
Elroy Air CEO details Chaparral drone ahead of $961M SPAC merger Dealroom
Thornton battery tech firm begins trading after $1.2B SPAC deal – The Business Journals
Thornton battery tech firm begins trading after $1.2B SPAC deal The Business Journals
David’s Bridal Plans to Spin Off Pearl in $350 Million SPAC Deal – PYMNTS.com
David’s Bridal Plans to Spin Off Pearl in $350 Million SPAC Deal PYMNTS.com
FORT Robotics lands $20M in fresh backing ahead of plans to go public – Technical.ly
FORT Robotics lands $20M in fresh backing ahead of plans to go public Technical.ly
South Korea’s Korai Flix to go public in US via $3.5 billion SPAC deal – Reuters
South Korea’s Korai Flix to go public in US via $3.5 billion SPAC deal Reuters
16 deals show space SPACs have a poor record for investors – SpaceQ
16 deals show space SPACs have a poor record for investors SpaceQ
TriGemX plans $246 million SPAC deal to fund migraine program – The Pharma Letter
TriGemX plans $246 million SPAC deal to fund migraine program The Pharma Letter
Houston-based SPAC taking battery startup Sakuu public after previous deal canceled – The Business Journals
Houston-based SPAC taking battery startup Sakuu public after previous deal canceled The Business Journals
ICR, the leading Capital Markets Communications and Advisory Firm, Publishes its Q3 2026 SPAC Market Update & Outlook – Business Wire
ICR, the leading Capital Markets Communications and Advisory Firm, Publishes its Q3 2026 SPAC Market Update & Outlook Business Wire
Investment firm TCGX picks migraine biotech TriGemX to take public via SPAC – Fierce Biotech
Investment firm TCGX picks migraine biotech TriGemX to take public via SPAC Fierce Biotech
TriGemX Bio is going public through SPAC to get its migraine prospect to market – Endpoints News
TriGemX Bio is going public through SPAC to get its migraine prospect to market Endpoints News
City goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to Nasdaq – Fierce Biotech
City goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to Nasdaq Fierce Biotech